Trulieve Expands NYSE Presence as MSO Seeks Broader Investor Access

Trulieve Deepens NYSE Integration

Trulieve is expanding its NYSE footprint to attract institutional investors who remain restricted from OTC cannabis plays. The Florida-based MSO, which already trades on the NYSE under the ticker TRLV, is enhancing its exchange presence through increased compliance reporting and investor-relations infrastructure designed to meet the expectations of traditional equity funds.

The timing aligns with Trulieve's $2.1 billion trailing-twelve-month revenue run rate and its 195-store footprint across 11 states. By deepening its NYSE integration, Trulieve is betting institutional allocators will prioritize exchange-listed cannabis equities over OTC-traded peers as federal policy shifts accelerate.

Why MSOs Pursue NYSE Listings

Exchange listings unlock access to index funds, ETFs, and institutional portfolios that can't hold OTC securities. U.S. cannabis operators remain federally illegal under the Controlled Substances Act. Yet several MSOs have secured NYSE or Nasdaq listings through reverse takeovers of Canadian shell companies or by maintaining Canadian business operations that satisfy exchange eligibility rules.

Trulieve's NYSE listing gives it a structural advantage over competitors still trading on the CSE or OTC markets. The exchange imposes stricter disclosure standards, quarterly earnings calls, and governance requirements—friction that institutional buyers view as risk mitigation.

Institutional Capital Remains Sidelined

Most U.S. pension funds, mutual funds, and ETFs still exclude cannabis holdings due to federal prohibition and internal compliance mandates. Even NYSE-listed cannabis stocks face exclusion from major indexes like the S&P 500 and Russell 2000, which require positive GAAP earnings and federal legal compliance.

Trulieve reported a net loss of $43 million in Q1 2026, weighed down by Section 280E tax burdens that prevent cannabis operators from deducting ordinary business expenses. The company's EBITDA margin of 28% demonstrates operational profitability. But GAAP losses keep it off index radars. An NYSE expansion strategy signals confidence that federal reform—whether through rescheduling or the SAFER Banking Act—will remove these barriers within the next 12-18 months.

Competitive Landscape and Peer Moves

Trulieve joins Curaleaf, Green Thumb Industries, and Verano in maintaining U.S. exchange listings, while Cresco Labs and AYR Wellness remain OTC-traded. The competitive advantage of an NYSE ticker becomes clearer during capital raises: exchange-listed MSOs consistently price secondary offerings at tighter discounts to market and attract larger institutional anchors.

For context, see the CannIntel topic hub on Trulieve's NYSE listing for the full regulatory and financial backstory. Trulieve's market cap of approximately $1.8 billion makes it the fourth-largest U.S. MSO by valuation, trailing Curaleaf, Green Thumb, and Verano.

What to Watch

The next catalyst is the DEA's final rescheduling rule, expected in Q3 2026, which could reclassify cannabis from Schedule I to Schedule III. That shift would eliminate 280E tax penalties and potentially open the door for limited institutional participation, though full banking access and index inclusion would still require Congressional action.

Trulieve's NYSE expansion is a pre-positioning move. If rescheduling lands and banking reform follows, the MSOs with exchange listings and institutional-grade IR infrastructure will capture the first wave of institutional inflows. They're building that infrastructure now.